Oncology Program

An oral BLT1 agonist that promotes tumor antigen presentation in preclinical models

30-40%

response rates

Most cancer patients do not benefit from immune checkpoint inhibitor therapy alone

The Critical Gap Upstream of Checkpoint Blockade

▶ T-Cell Priming Requirement
Immune checkpoint inhibitors release the brakes on the body's natural ability to kill cancer cells, but only when T cells are primed with tumor antigens.
▶ Cold Tumor Challenge
"Cold" tumors, such as pancreatic, microsatellite stable colorectal, and ovarian, lack primed T cells to respond to checkpoint blockade.
▶ Tumor Antigen Expression Requirement
Even when T cells are primed by antigen presentation machinery and unleashed by checkpoint blockade, they can clear tumors only if cancer cells express antigens. This requirement must be fulfilled to deliver durable responses.

TP-317 Activates the Immune Responses Required for Checkpoint Blockade

TP-317 activates immunogenic phagocytosis and antigen presentation to enhance checkpoint blockade efficacy in cold tumors
▶ Antigen Presentation
TP-317 promotes immunogenic phagocytosis of tumor debris, activating antigen presentation and T-cell priming rather than the immune silencing typical of efferocytosis.
▶ Reduced Immune Tolerance
By activating immunogenic clearance, TP-317 displaces efferocytosis that causes immune tolerance and tumor progression.
▶ Tumor Reprogramming
TP-317 reprograms tumors to present antigens — an effect confirmed by single-cell RNA analysis in multiple tumor types. This enables cytotoxic T-cells unleashed by checkpoint blockade to find and kill cancer cells. (Huang et al., 2025)

Preclinical Results in Syngeneic Tumor Models

Added to standard of care, TP-317 reduced tumor growth by a further 58–83%

Untreated control TP-317 alone Dual SOC Dual SOC + TP-317 *** ******* ******** ***** p < 0.001p = 0.038p = 0.010p = 0.052 −83%−67%−59%−58% 020406080100 Lung(LLC) Melanoma(B16F10) Colorectal(CT26) Pancreatic(KPC) Tumor growth vs control (%)

Mean ± SEM percent change in tumor volume, normalized to the untreated control of each study. Dual SOC is anti-PD-1 with cisplatin (LLC), anti-CTLA-4 (B16F10), 5-FU (CT26) or gemcitabine (KPC). Asterisks give the comparison with untreated control; brackets compare Dual SOC with Dual SOC plus TP-317.

A BLT1 antagonist abolishes the effect of TP-317

Untreated control * p = 0.002 effect abolished 050100150 Control TP-317 BLT1antagonist TP-317 +antagonist Tumor growth vs control (%)

CT26, day 12. BLT1 antagonist CP-105,696 50 mg/kg; TP-317 0.3 mg/kg oral. The antagonist alone did not differ from untreated control (p = 0.72).

Two-sided Mann-Whitney U, n = 7 to 9 per group: * p < 0.05, ** p < 0.01, *** p < 0.001. Comparisons without a mark did not reach significance.


Reference

Huang S, et al. Resolvin E1 Enhances Immune Checkpoint Inhibitor Therapy by Stimulating Tumor Antigen-Presentation. Cancer Res (2025) 85 (8_Supplement_1): 6912. https://doi.org/10.1158/1538-7445.AM2025-6912

Partner with Thetis

TP-317 in oncology is available for partnering alongside the IBD program.